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Abstract
The mechanisms leading to prostate cancer metas-
tasis are not understood completely. Although there
is evidence that the CXC chemokine receptor (CXCR) 4
and its ligand CXCL12 may regulate tumor dissemi-
nation, their role in prostate cancer is controversial.
We examined CXCR4 expression and functionality,
and explored CXCL12-triggered adhesion of prostate
tumor cells to human endothelium or to extracellu-
lar matrix proteins laminin, collagen, and fibronectin.
Although little CXCR4 was expressed on LNCaP and
DU-145 prostate tumor cells, CXCR4 was still active,
enabling the cells to migrate toward a CXCL12 gra-
dient. CXCL12 induced elevated adhesion to the endo-
thelial cell monolayer and to immobilized fibronectin,
laminin, and collagen. Anti-CXCR4 antibodies or
CXCR4 knock out significantly impaired CXCL12-
triggered tumor cell binding. The effects observed
did not depend on CXCR4 surface expression level.
Rather, CXCR4-mediated adhesion was established by
A5 and B3 integrin subunits and took place in the pres-
ence of reduced p38 and p38 phosphorylation. These
data show that chemoattractive mechanisms are in-
volved in adhesion processes of prostate cancer cells,
and that binding of CXCL12 to its receptor leads to
enhanced expression of A5 and B3 integrins. The find-
ings provide a link between chemokine receptor ex-
pression and integrin-triggered tumor dissemination.
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Introduction
Chemokinesare a family of low-molecular-weight (8–10kDa)
proinflammatory cytokines that bind to G-protein–coupled
receptors. Their primary functions are chemoattraction
and activation of specific leukocytes in diverse immuno-
inflammatory responses. However, increasing evidence
suggests that they also play key roles in neoplastic trans-
formation and passage of tumor cells through the endo-
thelial vessel wall and extracellular matrix. Among the
chemokines and chemokine receptors identified to date,
the membranous CXC chemokine receptor 4 (CXCR4) and
its ligand stromal-derived factor-1 (SDF-1, synonymous to
CXCL12) are thought to play a central role in regulating the
metastasis of many solid tumors, including those of the lung,
breast, and kidney.
The extent to which the CXCR4–CXCL12 axis is involved
in prostate cancer, the most common nondermatologic malig-
nancy worldwide, is still not clear. There is evidence that high
expression levels of CXCR4 and positive staining for its ligand
CXCL12 might correlate with the presence of metastatic dis-
ease in prostate cancer patients [1,2]. The binding of secreted
CXCL12 to CXCR4 at the tumor cell surface is assumed to
activate the cellular motor machinery and to trigger tumor
migration from the blood vessel into the target tissue. Never-
theless, the hypothesis of CXCR4-driven prostate tumor cell
adhesion has not yet been proven. Whether the CXCR4 sur-
face level in fact correlates with tumor aggressiveness has
not been established. Tumor cells isolated from patients with
prostate carcinoma compared to benign prostatic hyperpla-
sia have shown different migratory capacities in an invasion
chamber model, although the amount of CXCR4-expressing
cells did not differ between the groups [3]. In a similar model,
the same number of PC3 and LNCaP prostate carcinoma
cells moved toward a chemotactic CXCL12 gradient, although
fluorescence-activated cell sorter (FACS) analysis revealed
significantly higher levels of cell surface CXCR4 on LNCaP
when compared to PC3 [2,4]. In contrast to this, Darash-
Yahana et al. [5] detected no or very low CXCR4 surface ex-
pression on PC3 and LNCaP cell lines. Both cell types did not
respond to CXCL12. Immunohistochemical evaluation of PC-3
cells demonstrated uniform cytoplasmic—but no surface—
CXCR4 staining [6], and the analysis of prostate specimen
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from primary prostate cancer sections and prostate boneme-
tastases has not revealed CXCR4 surface localization [3,7].
These findings might conflict with the idea that prostate
tumor cell adhesion and migration are mediated by
CXCL12–CXCR4 interaction. If the concept of CXCR4-
mediated tumor invasion is valid, we should expect function-
ally active CXCR4 receptors along the tumor cell membrane.
In this study, we investigated whether the membrane of
prostate tumor cells is occupied by CXCR4. In the next step,
the involvement of CXCR4 in tumor cell adhesion and mi-
gration processes was evaluated.
Using DU-145 and LNCaP prostate tumor cells as cul-
ture model, we have demonstrated that CXCR4 was ex-
pressed on the cell surface, although to a very low extent.
The receptor amount was sufficient to respond to a CXCL12
stimulus, indicating that migratory activity does not depend
on receptor quantity. We demonstrate, for the first time, that
CXCR4 engagement triggers tumor cell adhesion to endo-
thelial cells as well as to extracellular matrix proteins. CXCR4
does not act as an anchoring molecule that allows firm
cellular attachment, but rather as a signaling receptor that
activates a5 and b3 integrin subunits. Moreover, we demon-
strate that the process of CXCR4 stimulation by CXCL12 is
accompanied by the downregulation of p38 MAPK and p38
MAPK phosphorylation.
Materials and Methods
Chemokines and Antibodies
Human CXCL12 was purchased from Strathmann (Am-
sterdam, The Netherlands), whereas phycoerythrin (PE)–
conjugated monoclonal antibodies against CXCR4 (IgG2a;
clone 12G5) and CXCR3 (IgG1; clone 49801.111) were pur-
chased from R&D Systems (Wiesbaden, Germany). Anti-
ERK1 (clone MK12), phospho-specific anti-ERK1/2 (pT202/
pY204; clone 20A), anti-JNK (clone 37), phospho-specific
anti-JNK (pT183/pY185; clone 41), anti-p38 (clone 27), and
phospho-specific anti-p38 (pT180/pY182; clone 30) mono-
clonal antibodies were obtained from BD Biosciences (Hei-
delberg, Germany). Integrin-linked kinase (ILK; clone 3),
focal adhesion kinase (FAK; clone 77), and phospho-specific
FAK (pY397; clone 18) were purchased from BD Bio-
sciences. Anti–b-actin monoclonal antibody was obtained
from Sigma (Taufenkirchen, Germany).
Cell Cultures
DU-145 and LNCaP prostate carcinoma cells were pur-
chased from DSMZ (Braunschweig, Germany). Tumor cells
were grown and subcultured in RPMI 1640 medium (Se-
romed, Berlin, Germany) supplemented with 10% fetal calf
serum (FCS), 100 IU/ml penicillin, and 100 mg/ml streptomy-
cin at 37jC in a humidified 5% CO2 incubator.
Human umbilical vein endothelial cells (HUVEC) were iso-
lated and harvested by enzymatic treatment with chymo-
trypsin. HUVEC were grown in Medium 199 (Biozol, Munich,
Germany), 10% FCS (Gibco, Karlsruhe, Germany), 10%
pooled human serum (Blood Bank of The German Red Cross,
Frankfurt am Main, Germany), 20 mg/ml endothelial cell growth
factor (Boehringer Mannheim, Mannheim, Germany), 0.1%
heparin (Roche, Basel, Switzerland), 100 ng/ml gentamycin
(Gibco), and 2% 1 M HEPES buffer (Seromed). To control the
purity of HUVEC cultures, cells were stained with fluores-
cein isothiocyanate– labeled monoclonal antibody against
factor VIII–associated antigen (von Willebrand factor; clone
F8/86; Dako, Hamburg, Germany) and analyzed microscopi-
cally or by FACScan [FL-1H (log) channel histogram analysis,
1  104 cells/scan; BD Biosciences]. Cell cultures with purity
>95% were serially passaged. Subcultures from passages 2
to 4 were selected for experimental use.
Transfection of Tumor Cells with Small Interfering
RNA (siRNA)
siRNA was constructed and directed against CXCR4
[gene accession no. NM_003467; sense: r(GCA GUC CAU
GUC AUC UAC A)dTdT; antisense: r(UGU AGA UGA CAU
GGA CUG C)dCdT]. LNCaP or DU-145 cells were trans-
fected at 70% confluence with 8 nM siRNA using RNAiFect
transfection reagent (Qiagen, Hilden, Germany). Optimum
transfection was achieved in RPMI 1640 medium sup-
plemented with 5% FCS and a 1:6 siRNA/RNAiFect ratio.
The viability of tumor cells was assessed by propidium
iodide double-stranded DNA intercalation or quantitative
fluorescence analysis of enzyme-catalyzed fluorescein–
diacetate metabolism.
Tumor Cell Adhesion and Migration
HUVEC were transferred to six-well multiplates (Falcon
Primaria; BD Biosciences) in complete HUVEC medium.
When confluency had been reached, DU-145 or LNCaP cells
were detached from culture flasks by accutase treatment
(PAA Laboratories, Co¨lbe, Germany), and 0.5  106 cells
were then added to the HUVEC monolayer for 60 minutes.
Subsequently, nonadherent tumor cells were washed off
using warmed (37jC) Medium 199. The remaining cells were
fixed with 1% glutaraldehyde.
Cell migration toward CXCL12 was examined using six-
well Transwell chambers (Greiner, Frickenhausen,Germany)
with 8-mm pores. DU-145 or LNCaP cells were removed from
culture flasks and resuspended at 0.5  106 cells/ml in
a serum-free culture medium. CXCL12 (0–500 ng/ml) was
placed in lower wells. Test cells were then placed in the
upper chamber for 60 minutes. After incubation, the upper
surface of the Transwell membrane was wiped gently with
a cotton swab to remove nonmigrating cells. Cells that mi-
grated to the lower surface of the membrane were stained
using hematoxylin.
In each experimental setting, adherent or migrated tumor
cells were counted in five different fields of a defined size
(5  0.25 mm2) using a phase-contrast microscope, and the
mean cellular adhesion/migration rate was calculated. For
neutralization studies, cells were pretreated with 20 mg/ml
anti-human CXCR4 or anti-human CXCR3 monoclonal anti-
bodies for 60 minutes, or tumor cells were transfected with
CXCR4 siRNA and collected 48 hours later. Cells were then
applied for adhesion and migration experiments.
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Attachment to Extracellular Matrix Components
Six-well plates were coated with collagen [diluted to
100 mg/ml in phosphate-buffered saline (PBS); Seromed],
laminin (diluted to 50 mg/ml in PBS; BD Biosciences), or fi-
bronectin (diluted to 50 mg/ml in PBS; BD Biosciences) over-
night. Plastic dishes served as background control. Plates
were washed with 1% bovine serum albumin (BSA) in PBS to
block nonspecific cell adhesion. Thereafter, 0.5  106 tumor
cells/well were added for 60 minutes. Subsequently, non-
adherent tumor cells were washed off, and the remaining
adherent cells were fixed with 1% glutaraldehyde and
counted microscopically. The mean cellular adhesion rate
(adherent cellscoated well  adherent cellsbackground) was cal-
culated from five observation fields.
Tumor Cell Binding to Immobilized Receptor
Protein Chimeras
Chimeric receptor globulins were constructed as de-
scribed previously [8]. Proteins containing the extracellular
domain of E-selectin, ICAM-1, VCAM-1, or P-selectin were
expressed in COS-7 cells. COS-7 cells were transfected with
3 mg of plasmid DNA using the DEAE/dextran method. Seven
days after transfection, supernatants were collected and
stored at 20jC. The concentration of the receptor globulin
chimeras was determined by enzyme-linked immunosorbent
assay using a monoclonal rat anti-human IgG antibody
conjugated to peroxidase. Round culture dishes (Falcon
Primaria; BD Biosciences) were incubated with a spot of
50 ml of goat–anti-human IgG (Sigma) at a concentration of
10 mg/ml in 50 mM Tris, pH 9.5, for 90 minutes. Dishes were
washed thrice with PBS (Seromed) and blocked with 1%
BSA overnight at 4jC. The dishes were subsequently incu-
bated with 1 ml of cell culture supernatant, containing 5 mg/ml
E-selectin, ICAM-1, VCAM-1, or P-selectin IgG fusion pro-
tein for 30 minutes at 20jC. Dishes were then washed thrice,
and tumor cells were resuspended at a density of 0.5 
106 cells/ml in binding buffer for 30 minutes [9] and trans-
ferred to culture dishes. Thereafter, nonadherent cells were
washed off, and the remaining cells were counted using a
phase-contrast microscope. Five observation fields were
chosen at random in each dish, and the mean value of the
number of adherent cells per field was calculated.
Evaluation of CXCR4 Surface Expression
DU-145 or LNCaP cells were detached from culture flasks
by accutase treatment, washed in blocking solution (PBS
and 0.5% BSA), and then incubated for 60 minutes at 4jC
with PE-labeled anti-CXCR4 monoclonal antibody. To sepa-
rately analyze intracellular CXCR4 content, cells were fixed
and permeabilized (Fix & Perm; Biozol-An der Grub Bio-
research, Eching, Germany) before adding the monoclo-
nal antibody. CXCR4 expression on tumor cells was then
measured using FACScan [FL-2H (log) channel histogram
analysis; 1  104 cells/scan] and expressed as mean fluo-
rescence units (MFU). Mouse IgG2a-PE (Cymbus Biotech-
nology, Hofheim, Germany) was used as isotype control.
To explore CXCR4 localization, tumor cells were trans-
ferred to round cover slips, which were placed in a 24-
well multiplate. On reaching confluency, cell cultures were
washed twicewith PBS (with Ca2+ andMg2+) and then fixed in
cold (20jC) methanol/acetone (60/40 vol/vol). Sub-
sequently, cells were washed again with PBS (without Ca2+
and Mg2+) and afterward washed once with blocking buffer
(0.5% BSA in PBS without Ca2+ and Mg2+). After removing
the washing buffer, cells were incubated for 60 minutes with
PE-conjugated anti-CXCR4monoclonal antibody. To prevent
photobleaching of the fluorescent dye, cover glasses with
stained cells were taken out of the wells, and residual liquid
was removed. The cells were then embedded in an antifade
reagent/mounting medium mixture (ProLong Antifade Kit;
MoBiTec, Go¨ttingen, Germany) and mounted on slides. The
slides were viewed using a confocal laser-scanning micro-
scope (LSM 10; Zeiss, Jena, Germany) with a plan neofluar
100/1.3 oil immersion objective.
Western Blot Analysis
CXCR4. Total CXCR4 content was evaluated by Western
blot analysis. DU-145 or LNCaP cell lysates were applied to a
7%polyacrylamide gel and electrophoresed for 90minutes at
100 V. The protein was then transferred to nitrocellulose
membranes. After blocking with nonfat dry milk for 1 hour,
the membranes were incubated overnight with anti-CXCR4
antibody (dilution 1:100). HRP-conjugated goat–anti-mouse
IgG (dilution 1:5000;UpstateBiotechnology, LakePlacid, NY)
served as secondary antibody. The membranes were briefly
incubated with ECL detection reagent (ECL; GE Healthcare,
Freiburg, Germany) to visualize the proteins and were ex-
posed to an X-ray film (Hyperfilm EC; Amersham).
Integrins and signaling proteins. Cell lysates were pre-
pared from unstimulated cells or after stimulation with
500 ng/ml CXCL12. Western blot analysis was performed
using the following monoclonal antibodies: anti-integrin b1 (1:
2500), anti-integrin b3 (1:2500), anti-integrin b4 (1:250), anti-
integrin a2/VLA2a (1:250), anti-integrin a5 (1:5000), anti-
integrin aL/LFA-1a (1:500), and anti-integrin aV (1:250) (all
from BD Biosciences). Intracellular signaling cascade was
evaluated using appropriate monoclonal antibodies that rec-
ognize the phosphorylated form of the proteins or total
proteins (see above).
mRNA Expression of CXCR4
mRNA expression of CXCR and CXCL was evaluated by
reverse transcriptase polymerase chain reaction (RT-PCR).
Tumor cells were seeded in 50-ml culture flasks (growth
area, 25 cm2; Falcon Primaria). Total RNA was extracted
using RNeasy kit (Qiagen), and RNA samples were then
treated with 80 U/ml RNAse-free DNAse I (Boehringer
Mannheim) for 60 minutes at 37jC to eliminate amplifiable
contaminating genomic DNA. Subsequently, samples were
incubated for 10 minutes at 65jC to inactivate DNAse.
Complementary DNA was synthesized from 1 mg of total
RNA per sample with a 60-minute incubation at 42jC, using
the Moloney murine leukemia virus reverse transcriptase
(Invitrogen, Karlsruhe, Germany) and oligo-(dT) priming
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(Boehringer Mannheim). Amplification was carried out using
gene-specific primers and Platinum-Taq polymerase (Invi-
trogen) in a Mastercycler Gradient thermocycler (Eppendorf,
Hamburg, Germany). The primer sequences for CXCR4 were
as follows: 5V GGTGGTCTATGTTGGCGTCT 3V (sense) and
5V TGGAGTGTGACAGCTTGGAG 3V (antisense). Internal
controls for the RT-PCR reaction were performed by running
parallel reaction mixtures with the housekeeping gene
GAPDH: 5V ATCTTCCAGGAGCGAGATCC 3V (sense) and
5V ACCACTGACACGTTGGCAGT 3V (antisense). Reactions
were performed in the presence of 0.5 ml of cDNA, with an
initial incubation step at 94jC for 5minutes. Cycling conditions
consisted of denaturation at 94jC for 60 seconds, annealing
at 60jC for 60 seconds, and extension at 72jC for 60 seconds
over 35 cycles. The reaction was completed by another 10-
minute incubation step at 72jC. PCR products were sub-
jected to electrophoresis in 2% agarose gel and visualized by
ethidium bromide.
Statistical Analysis
All experiments were performed three to six times. Sta-
tistical significance was investigated by the Wilcoxon-Mann-
Whitney U test. Differences were considered statistically
significant at P < .05.
Results
CXCR4 Expression Profile in DU-145 and LNCaP Cells
To follow the expression pattern of CXCR4 in prostate
tumor cells, two different prostate tumor cell lines, DU-145
and LNCaP, were employed. In doing so, the CXCR4
‘‘route’’—analysis of the CXCR4-encoding mRNA, cytoplas-
mic accumulation of CXCR4 proteins, and membrane pre-
sentation of CXCR4 receptors—was traced. Strong CXCR4
mRNA activity was observed in DU-145 cells, whereas
moderate CXCR4 mRNA activity in LNCaP cells was noted
(Figure 1A). Western blot analysis revealed distinct amounts
of CXCR4 proteins in DU-145 cells and a lower CXCR4
protein content in LNCaP cells (Figure 1B). The next step
involved examining the CXCR4 surface expression level on
both cell lines. Histogram plots revealed very limited fluores-
cence intensity in both cell lines, making data interpretation
difficult (Figure 1C). To verify the specificity and integrity of
the anti-CXCR4 antibody, experiments were repeated using
HUVEC cultures as positive controls. According to earlier
data [10,11], distinct amounts of CXCR4 have been de-
tected on HUVEC (Figure 2A). In addition, DU-145 and
LNCaP cells were permeabilized and then marked again
with the anti-CXCR4 antibody. The procedure resulted in en-
hanced fluorescence signals, demonstrating high amounts
of intracellular CXCR4 proteins (Figure 2, B and C), con-
cordant with Western blot results. Thus, the integrity of the
antibodies used has been proven, and we conclude that
CXCR4 receptors are present on the tumor cell membrane,
although at a very low level. Confocal microscopy of DU-
145 cells showed intracellular localization of CXCR4, but
also weak receptor accumulation along intercellular bound-
aries (Figure 3).
Functionality of CXCR4 Receptor
Migration experiments were carried out to test whether
the few CXCR4 receptors detected on the prostate tumor cell
membrane are functionally active. Dose–response analysis
revealed a strong chemotactic activity of both DU-145 and
LNCaP cells, which was maximal when 500 ng/ml CXCL12
was applied (data not shown). Therefore, we used this con-
centration in subsequent neutralization studies.
The number of LNCaP and DU-145 cells migrating in
response to CXCL12 was significantly higher than that
for cells not exposed to CXCL12 as a chemoattractant.
CXCL12-dependent chemotaxis was neutralized by treat-
ment with the anti-CXCR4 antibody, but not with anti-
CXCR3 antibody (Figure 4). Tumor cells in which CXCR4
had been knocked down by siRNA did not respond to a
CXCL12 stimulus, whereas cells treated with scrambled
siRNA responded (Figure 4). Nonresponding cells remained
viable, as confirmed by propidium iodide double-stranded
DNA intercalation or quantitative fluorescence analysis of
enzyme-catalyzed fluorescein–diacetatemetabolism. These
experiments demonstrated that CXCR4 is functionally active
and that CXCL12 specifically acts on CXCR4.
CXCR4-Driven Adhesion to Endothelial Cells
and Extracellular Matrix
DU-145 or LNCaP cells strongly attached to HUVEC (DU-
145 > LNCaP) after 60 minutes (Figure 5), whereas the
adhesion rate of CXCR4 siRNA-transfected cells was signif-
icantly reduced. Tumor cells that were treated with scram-
bled siRNA attached to HUVEC to a similar extent as
nontreated control cells.
In a similar fashion, the binding of DU-145 or LNCaP cells
to extracellular matrix components was also CXCR4-
dependent. Figure 6 shows representative data obtained
with DU-145 or LNCaP tumor cells. The percentage of
adherent cells differed according to the matrix protein used.
Maximum adhesion capacity was measured on fibronectin-
and laminin-coated plates; a lower binding rate was seen
when culture plates were precoated with collagen. Tumor
cells that had lost their CXCR4 receptors by siRNA knock-
down showed less binding activity than control tumor cells
or cells pretreated with scrambled siRNA. The effect was
independent of the matrix component used.
These data, therefore, indicate that the adhesion of pros-
tate tumor cells to the endothelium or the matrix is mediated
by CXCR4.
CXCR4 Receptors Serve as Signal Transmitters
The adhesion experiments demonstrated that CXCR4
participates in the interaction of prostate tumor cells with
the endothelium or the extracellular matrix. However, they
did not explain how CXCR4 contributed to the adhesion pro-
cess. Two options seemed to be possible: 1) CXCR4 anchors
the tumor cells to a specific ligand expressed on endothelial
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cells and matrix proteins, or 2) CXCR4 modifies further
receptors expressed on tumor cells, which then regulate
adhesion to endothelial cells and matrix proteins. To assess
whether CXCR4 serves as an adhesion receptor itself or if
CXCR4 activates further receptors relevant for the adhesion
process, the following experimental strategy was employed:
Tumor cells were stimulated with CXCL12 and subsequently
neutralized with CXCR4monoclonal antibodies, or they were
initially blocked with anti-CXCR4 monoclonal antibodies
and subsequently treated with CXCL12. Cells were then
allowed to attach to endothelium or matrix proteins. We found
that cells treated with CXCL12—before CXCR4—receptors
were blocked, and their adhesion and binding rate were en-
hanced, similar to those cells that were treated with CXCL12
alone (Figure 7, representative of HUVEC and fibronectin).
However, when CXCR4 receptors were blocked first,
Figure 1. Expression of CXCR4 in LNCaP and DU-145 prostate tumor cells. (A) PCR analysis demonstrates strong CXCR4 mRNA expression in DU-145 cells and
moderate CXCR4 mRNA expression in LNCaP cells (fragment length, 346 bp). Internal control for the RT-PCR reaction was performed by running parallel reaction
mixtures with the housekeeping gene GAPDH (fragment length, 509 bp). The figure shows one of four representative experiments. (B) Western blot analysis of
CXCR4 in LNCaP and DU-145 tumor cells. The monoclonal antibody clone 12G5 was used to recognize CXCR4. -Actin served as internal control. One of three
representative experiments is shown. (C) Fluorescence analysis of CXCR4 surface expression. A PE-conjugatedmonoclonal antibody anti-CXCR4, clone 12G5, was
used to analyze CXCR level. A mouse IgG2a-PE served as isotype control. Fluorescence was analyzed using a FACScan flow cytometer, and a histogram plot (FL2,
height) was generated to show PE fluorescence. Fluorescence was expressed as MFU. The mean values of MFU from six experiments are given below each
representative histogram.
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CXCL12 was unable to upregulate cell attachment. Ob-
viously, CXCR4 is not required to attach the tumor cells to
their counterparts. Rather, receptor engagement by CXCL12
is the event critical to managing cell adhesion. Therefore,
CXCR4 does not directly modulate cell binding, but is neces-
sary to transmit CXCL12-induced signals, which activate
adhesion-specific receptors.
To identify these receptors, DU-145 or LNCaP cells were
added to plates precoatedwith immobilized ICAM-1, VCAM-1,
E-selectin, or P-selectin adhesion proteins. The proteins
selected are expressed along the vessel wall and are pos-
sible candidates for tumor cell/endothelial cell interaction.
Prostate cells mainly attached to E-selectin; only a few cells
bound to ICAM-1, VCAM-1, or P-selectin (data not shown).
The same binding behavior was observed when siRNA-
treated tumor cells were used, indicating that CXCR4 does
not regulate selectin or ICAM/VCAM–driven processes in
our in vitro model.
Remarkably, b3 and a5 integrin subunits became strongly
upregulated when prostate tumor cells were stimulated with
CXCL12 (Figure 8A). The level of a2 (the expression of which
was very low), b1, b4, and aV subunits did not change in
CXCL12-treated cells compared to nontreated controls (data
not shown). CXCL12 evoked ILK and FAK upregulation and
enhanced FAK phosphorylation. Integrins mediated binding
to the extracellular matrix and, according to our data, the
CXCL12-induced adhesion of DU-145 cells to HUVEC, fi-
bronectin, laminin, or collagen was inhibited by b3- and/or a5-
blocking antibodies (Figure 8C). This suggests that CXCR4
alters b3 and a5 integrins and cell–endothelium and cell–
Figure 2. Integrity of anti-CXCR4 monoclonal antibodies. HUVEC were used as positive controls, and CXCR4 surface expression of unfixed cells was evaluated by
the PE-conjugated monoclonal antibody anti-CXCR4 clone 12G5 (A). Mouse IgG2a-PE served as isotype control. In the second part, DU-145 (B) or LNCaP (C)
cells were permeabilized, and fluorescence analysis of intracellular CXCR4 was carried out thereafter. Each figure demonstrates a significant fluorescence shift
after labeling the cells with CXCR4-PE. One of three representative experiments is shown. The mean values of MFU from six experiments are also given.
Figure 3. Confocal analysis of CXCR4 distribution. DU-145 tumor cells were
grown in standard medium. Unconjugated monoclonal antibody clone 12G5
was used to analyze CXCR4. Indocarbocyanine (Cy3)–conjugated goat–anti-
mouse IgGwas added as secondary antibody. The figure shows distinct CXCR4
expression at intercellular boundaries (arrows) and strong intracellular accumu-
lation (scale, 10 M; original magnification, 100/1.3 oil immersion objective).
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matrix adhesion, which is dependent on b3 and a5. This pro-
cess is specifically attributable to CXCR4 because blocking
of CXCR3 receptors did not prevent CXCL12-evoked cell
binding (data not shown).
CXCR4 Downregulates p38 MAPK
In a further step, CXCL12-induced intracellular signaling
in DU-145 tumor cells was analyzed. No difference was ob-
served between the total amount of ERK1 and JNK proteins
Figure 4. CXCR4 expressed on DU-145 and LNCaP cells is functionally active. Tumor cell migration toward CXCL12 was assessed in a Transwell chamber assay.
DU-145 or LNCaP cells were seeded in the upper chamber, and 500 ng/ml CXCL12 was placed in the lower well. Cells that migrated to the lower surface of the
membrane were stained by hematoxylin and counted. In control experiments, a medium without CXCL12 was used. Statistical significance was investigated by the
Wilcoxon-Mann-Whitney U test. To demonstrate CXCR4 dependence, tumor cells whose CXCR4 was blocked by monoclonal antibodies or whose CXCR4 was
knocked down by siRNA were also applied in parallel experiments. Scrambled siRNA or nonspecific IgG served as controls. Knockdown was controlled 48 hours
after RT-PCR and Western blot analysis (right panel). One of six representative experiments is shown. *Significantly different from controls; #significantly different
from nontreated cells moving toward CXCL12.
Figure 5. Adhesion of DU-145 or LNCaP cells to HUVEC depends on CXCR4. Control tumor cells, tumor cells treated with scrambled siRNA, or tumor cells whose
CXCR4 was knocked down were activated with 500 ng/ml CXCL12 and then added at a density of 0.5  106 cells/well to HUVEC monolayers for 60 minutes.
Nonadherent tumor cells were washed off in each sample; the remaining cells were fixed and counted in five different fields (5  0.25 mm2) using a phase-contrast
microscope. Mean values were calculated from five counts. Mean adhesion capacity is depicted as counted cells per square millimeters. One of six representative
experiments is shown. **Significantly different from controls (P < .01).
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Figure 6. Adhesion of prostate tumor cells to extracellular matrix proteins depends on CXCR4. DU-145 (A) or LNCaP (B) cells treated with scrambled siRNA, or
DU-145/LNCaP cells whose CXCR4 was knocked down were activated with 500 ng/ml CXCL12 and then added to immobilized fibronectin, laminin, collagen, or
nonspecific poly-L-lysine (PLL) at a density of 0.5  106 cells/well for 60 minutes. Nontreated cells served as controls. Nonadherent tumor cells were washed off in
each sample; the remaining cells were fixed and counted in five different fields (5  0.25 mm2) using a phase-contrast microscope. Mean values were calculated
from five counts. Specific adhesion capacity (background adhesion on a plastic surface was subtracted from adhesion to matrix proteins) is depicted as counted
cells per square millimeters. One of six representative experiments is shown. **Significantly different from controls (P < .01).
CXCR4 Modulates Integrins in Prostate Cancer Engl et al. 297
Neoplasia . Vol. 8, No. 4, 2006
(CXCL12-activated versus untreated control cells), and only
weak phosphorylation was measured. Phosphorylation did
not change after CXCL12 incubation. However, p38 MAPK
was reduced after CXCL12 treatment. p38 phosphorylation
was strongly downregulated after CXCL12 stimulation in DU-
145 cells (Figure 8B). CXCR4, therefore, strongly influences
the p38 pathway.
Discussion
CXCL12 and its receptor CXCR4 may be involved in all
stages of tumor development and progression. CXCL12
promotes the growth of gastrointestinal, pancreatic, breast,
and ovarian cancer cells [12–15]. There is growing evidence
that CXCL12 and CXCR4 regulate the migration and metas-
tasis of small cell lung cancer cells [16] and are implicated
in organ-specific metastases of head and neck squamous
cell carcinoma [17]. CXCR4 expression is associated with re-
currence, survival, and liver metastasis in colorectal cancer
patients [18] and predicts poor prognosis in patients with
malignant melanoma [19].
Although there is no doubt that CXCR4 also plays a role
in prostate cancer, it is not clear how the CXCR4–CXCL12
axis functions. Analysis of clinical samples has demon-
strated elevated CXCR4 protein expression in both localized
and metastatic prostate cancers [7]. A study has revealed a
higher CXCR4 expression rate in patients with bone metas-
tasis than in those with no bone metastasis [20].
We speculate that CXCR4 directs tumor cell traffic to
distant organs in a manner that does not correspond to
CXCR4 expression level. Furthermore, chemotaxis toward
a CXCL12 gradient may not exclusively explain the poten-
tial for neoplastic cells to migrate and invade other tissues.
Tumor cell contact with the vessel wall and the underlying
matrix must occur to allow the penetration and initiation
of secondary tumors. Our results indicate that CXCR4/
CXCL12 is an important mediator for the adherence of pro-
state tumor cells to the endothelium and for interactions with
extracellular matrix proteins such as laminin, fibronectin,
and collagen.
Evidence has shown that CXCR4 proteins preferentially
accumulate in the cytoplasm of DU-145 and LNCaP tumor
cells. However, the amount of CXCR4 appearing at the cell
surface was limited, and confocal analysis was necessary
to clearly demonstrate receptor localization along cell bound-
aries. CXCR4 surface receptors were functionally active,
Figure 7. CXCR4 does not anchor prostate tumor cells to HUVEC or matrix proteins, but transmits signals after receptor engagement by CXCL12, which then
allows cell adhesion. The study design was created as follows: 1) DU-145 or LNCaP cells were activated with 500 ng/ml CXCL12 (control experiments were carried
out without CXCL12 activation); or 2) DU-145 or LNCaP cells were activated with 500 ng/ml CXCL12, and CXCR4 was blocked thereafter by monoclonal antibodies
(CXCL12-AB); or 3) DU-145 or LNCaP cells were first treated with anti-CXCR4 monoclonal antibodies and then activated with 500 ng/ml CXCL12 (AB-CXCL12).
Tumor cells were then added to HUVEC or immobilized fibronectin. Mean adhesion from five different fields (5  0.25 mm2) was evaluated after 60 minutes.
Adhesion capacity was strongly reduced in DU-145 or LNCaP cells when CXCR4 was blocked before CXCL12 was applied. Adhesion was not reduced when tumor
cells were activated with CXCL12 followed by initiation of receptor blockade or when cells were treated with unspecific IgG. One of six representative experiments
is shown. **Significantly different from controls (P < .01); ##significantly different from cells activated with CXCL12.
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and chemoinvasion took place regardless of the receptor
amount. Even more DU-145 cells responded to CXCL12
than LNCaP cells, although higher CXCR4-specific fluores-
cence was detected on LNCaP cells. In accordance with
our observation, LNCaP and PC3 tumor cells have recently
been shown to migrate in a comparable fashion and to
invade through extracellular matrix components in response
to CXCL12, at rates not corresponding to CXCR4 surface
expression [2]. Obviously, receptor saturation occurs at
a very low level and, consequently, quantitative receptor en-
hancement beyond a specific threshold will not acceler-
ate migratory processes of prostate tumor cells. Therefore,
it is not surprising that overexpression of CXCR4, induced
by transfection, does not upregulate the chemotactic poten-
tial of tumor cells [5]. Presumably, CXCL12 release is critical
for cell migration, and cancerous cells expressing CXCR4
are more likely to seed distant sites where high levels of
CXCL12 are found. Indeed, our findings demonstrated
CXCL12 concentration to be the limiting factor for chemo-
tactic activity.
An argument against our hypothesis might be that enzy-
matic detachment of the cells might downregulate CXCR4
surface expression, leading to reduced fluorescence signals.
However, pilot studies revealed that accutase treatment did
not alter surface epitopes, in contrast to trypsin, which is
most often used to detach cells. Therefore, although we
cannot completely rule out slight CXCR4 modifications by
accutase, this assumption seems not to be very likely.
The model of CXCR4-triggered chemotaxis might ex-
plain the improved motility and invasiveness acquired by
the tumor cells after extravasation into the target tissue.
We now document that CXCR4 plays a decisive role in
controlling preinvasive binding events, as well as tumor
cell interaction with the extracellular matrix. CXCL12-en-
hanced attachment of DU-145 and LNCaP cells to endo-
thelial cells, laminin, fibronectin, and collagen is a process
that can be antagonized by CXCR4-specific antibodies or
CXCR4 knockdown. As we demonstrated in CXCL12 activa-
tion studies, CXCR4 did not regulate adhesion itself,
but served as a signaling element to modulate integrin a5
Figure 8. CXCL12 modulates integrin expression; ILK, FAK, and FAK phosphorylation (FAKphospho); and p38-dependent pathways. (A and B) DU-145 cells were
incubated with 500 ng/ml CXCL12 for 4 hours. Cell lysates were analyzed by specific antibodies against integrin 3 or a5. FAK and ILK were examined by mouse
IgG1 monoclonal antibodies (1:1000), as indicated in Materials and Methods section. Intracellular signaling cascade was evaluated using appropriate monoclonal
antibodies recognizing the phosphorylated form of the p38 protein [p38 (pT180/pY182)] or p38 in total (p38a). -Actin served as internal control. One of three
representative experiments is shown. (C) The CXCL12-mediated adhesion of DU-145 cells to HUVEC or extracellular matrix proteins is 3- or a5-dependent.
CXCL12-activated DU-145 cells were preincubated with 3- or a5-blocking antibodies or the corresponding IgG isotype control, and then added to HUVEC
monolayers or immobilized collagen, laminin, or fibronectin. Adherent cells were counted after 60 minutes. Adhesion of cells not treated with monoclonal antibodies
was set at 100%. Adhesion blockade diminished adhesion to HUVEC and to extracellular matrix proteins. One of three representative experiments is shown.
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and b3 expression. Blocking the integrin subunits led to a
decrease of cell binding, indicating that these receptors are
indeed involved in tumor cell/endothelial cell/extracellular
matrix interaction.
Disseminated prostate tumors are characterized by al-
tered integrin expression. In particular, aVb3, which is not
expressed in normal prostate tissue but is upregulated in
prostatic adenocarcinoma, has been linked to invasive be-
havior [21]. Nemeth et al. [22] pointed to the importance of
a5b3 integrins in controlling the growth and metastasis of
prostate cancer cells in the bone, and overexpression of a5
subunits increased the adhesion of the cell line PC-3 to
collagen type I, fibronectin, and laminin [23]. The regulation
of a5- and b3-mediated tumor cell adhesion by CXCL12 could
therefore play a key role during cell homing into, and traf-
ficking inside, the bone.
This is the first report to demonstrate CXCR4-triggered
integrin activation in prostate cancer. However, this observa-
tion might not be restricted to prostate cancer, and the con-
cept of chemokine–integrin interplay may be valid for other
tumor types. It has been postulated that adhesion of human
melanoma cells to endothelial cells depends on crosstalk
between CXCR4 and b1 integrin chains [24]. The binding
of small cell lung cancer cells to the extracellular matrix
seems to be mediated by a2, a4, a5, and b1 integrins, along
with CXCR4 activation [16]. Based on available data, we
hypothesize that CXCR4 represents a ubiquitous receptor
molecule expressed on normal and neoplastic tissues. How-
ever, integrin equipment might be different among normal
and metastatic cells and between specific tumor cell types,
allowing tumor transmigration after the occupation of CXCR4
by CXCL12 had taken place.
Surprisingly, our experiments did not reveal any effects of
CXCL12 on tumor cell binding to immobilized VCAM, ICAM,
E-selectin, and P-selectin, although CXCR4 knockdown or
CXCR4 receptor blockade significantly reduced the adhe-
sion of DU-145 or LNCaP cells to HUVEC. Obviously, the
interaction of endothelial CAM or selectins with their respec-
tive ligands will not be influenced by the CXCR4–CXCL12
axis. CXCL12 was found to be a rapid and potent stimulator
of CD34+ stem/progenitor cells, leading to the formation of
actin-containing protrusions with CD44 adhesion receptors
located at their tips [25]. It cannot be ruled out that a similar
crosstalk exists between CD44 and CXCR4 signaling in
prostate tumor cells. Nevertheless, we should be aware that
a5- and b3-blocking antibodies partially prevented tumor
binding to HUVEC; therefore, these integrins also seem
involved in tumor cell/endothelial cell interaction. However,
as integrins predominantly connect tumor cells to the extra-
cellular matrix, we speculate that downregulation of adhesive
capacity might be caused by preventing tumor cell anchor-
age to matrix proteins expressed on endothelial cells rather
than to the endothelial cells themselves. Indeed, HUVEC
cultures produce and build a complex matrix network con-
sisting of fibronectin, laminin, and collagen [26].
Looking at the signaling components participating in
CXCR4-mediated cell adhesion, we found that enhanced
a5 and b3 integrin expression was paralleled by reduced
protein expression and phosphorylation of p38 MAPK.
Taichman et al. [6] observed a rapid phosphorylation of
ERK proteins in PC-3 cells within 5 minutes of CXCL12
stimulation, and CXCR4-mediated activation of both p38
MAPK and ERK has been ascribed to human embryonic
kidney 293 cells [27]. This might conflict with our results.
However, both citations are based on a short-course stimu-
lus. Our experimental strategy was designed to evaluate
intracellular signaling at the same time point that integrin
upregulation became obvious (i.e., 4 hours after adding
CXCL12). Presumably, CXCR4-mediated activation and pro-
tein increase of MAPKmolecules reveal an early intracellular
event, whereas specific downregulation of p38 and p38
phosphorylation might occur later. In fact, ERK phosphory-
lation returned to baseline after 30 minutes in the Taichman
et al. study. In a murine pre-B cell line, p38 was slightly
enhanced 30 minutes following CXCL12 binding to CXCR4,
but was reduced below controls thereafter [28].
p38 has long been attributed to be a proapoptotic factor,
the downregulation of which triggers enhanced cell survival
and growth [29,30]. However, novel reports also point out
the role of p38 in cell invasion processes. In this context,
the adhesion of prostate carcinoma cell lines becomes
reduced in the presence of a p38 inhibitor [31,32]. Very re-
cently, Huang et al. [33] observed that genistein blocks the
activation of p38, thereby inhibiting processes closely linked
to metastasis.
This might speak for a sensitive balance between tumor
cell invasion and tumor cell proliferation, channeled by p38.
The engagement of CXCR4 evoked distinct modifications of
p38 content and activity in our experiments, although our
results do not explain if reduction of p38 contributes to
enhanced a5 and b3 integrin synthesis or if integrin elevation
creates a negative feedback loop that downregulates p38.
Interestingly, high a5b1 integrin expression in several tumor
cell lines has been found to be accompanied by low p38
activity [34]. These authors concluded from their study that
a5b1 integrins are responsible for blocking p38 activity, which
drives tumor cells toward persistent growth. According to this
hypothesis, new data highlight the critical contributions of
p38 in the negative regulation of cell cycle progression, the
attenuation of oncogenic signals, and the positive regulation
of several tumor-suppressor pathways [35–37].
Based on this, it seems plausible that a5 and b3 integrins
participate in the interaction of prostate tumor cells with
extracellular matrix proteins that allow solitary cells or small
groups of cells to establish metastases and, after a period of
time, shift from invasive to proliferative behavior.
Our results show that CXCR4 receptors are expressed on
prostate tumor cells, enabling the cells to migrate toward a
CXCL12 gradient and to contact endothelial cells and extra-
cellular matrix proteins. The effects observed did not depend
on CXCR4 surface expression level. CXCR4-mediated ad-
hesion was established by a5 and b3 integrin subunits and
took place in the presence of reduced p38 and p38 phos-
phorylation. Presumably, reduced p38 prevents apoptosis
and allows rapid tumor growth necessary for survival in a
distant organ.
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